An observational study in Breast Diseases, sponsored by Korea University Ansan Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Korea University Ansan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Breast Diseases with a site in Korea, Republic of — 2 open to participants now, 5 under way, 4 of them phase 3. Breast Diseases · Korea, Republic of.
Among the 12 studies in Breast Diseases with a site in Korea, Republic of, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 11th registered.
148 studies on the registry are indexed under Breast Diseases; 26 are open to participants now.
Browse Breast Diseases studies →2 of the 12 studies in Breast Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of, United States, France and 6 more countries
Ages 18–130
Stemline Therapeutics, Inc. · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 20 Breast Diseases studies recruiting now, 14 (70%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 20 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7
First in 2009; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 594 is above the median of 213 across 50 observational studies indexed under Breast Diseases.
Median enrollment 201 across the 10 interventional studies, 317 across the 2 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 8 most frequent:
Korea University Ansan Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Korea University Ansan Hospital has 1 study filed under Breast Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Breast Diseases with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Breast Diseases with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Human soft tissue such as breast tissue has viscoelasticity property. However, most ultrasound has only been measured for elasticity and viscosity has been neglected. Shear wave elastography (SWE) is a ultrasound technique that quantifies tissue elasticity. Shear wave dispersion (SWD) imaging is a newly developed ultrasound technique that evaluates the dispersion slope of shear waves, which is related to the viscosity of biological tissues. The goal of this retrospective study was to compare diagnostic performance between SWE and SWD to distinguish benign from malignant breast masses and to investigate additional role of SWD. Using histological diagnosis of breast lesions as a standard reference, quantitative indices of SWE and SWD were evaluated to diagnose breast cancer, and the diagnostic performance of SWE and SWD was compared.
This retrospective study was approved by our institutional review board, which waved the requrement for informed consent. The investigators obtained quantitative parameters of SWE and SWD of solid breast lesions before biopsy. The investigators measured average tumor elasticity and tumor-to-fat elasticity ratio on SWE and average tumor dispersion and tumor-to-fat ratio and on SWD from each breast lesion. Diagnostic performance of SWE and SWD was compared using the area under the curve (AUC), sensitivity, specificity, and accuracy.
The study population should fulfill the following criteria as follows:(a) histologically confirmed breast lesions and (b) shear wave elastography and dispersion ultrasound performed before biopsy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer
Elastography and dispersion parameters to determine benign or malignant tumors
The elastography and dispersion ultrasound parameter values correlated with histological results.
Time frame: baseline, pre-biopsy
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Aug 2021, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Ansan Hospital